Ann: Results of Meeting, page-5

90% decrease in company value since commencement of phase2 nanabis. It was successful after 2 years and resulted in 50% decrease in sp. I think large vote against it was due to this. Perhaps heading into phase3 will have opposite effect as other biotech with unsuccessful trial and no income worth over 100mill$.

why issue cheap options when sp performance is worse off after successful phase2 doesnt add up. Hence the large vote against imo.

interesting 24 months ahead